Vimarsana
Biggest News Aggregation in the World

Morf 057 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Morf 057. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Morf 057 Today - Breaking & Trending Today

25% of Patients Achieve Endoscopic Remission in Phase 2a EMERALD-1 Trial for MORF-057 - Vimarsana News

25% of Patients Achieve Endoscopic Remission in Phase 2a EMERALD-1 Trial for MORF-057

Published: September 25, 2023

Data from the phase 2a trial showed 25.7% of patients with UC demonstrated endoscopic improvement and 45.7% achieved clinical response after week 12.

Source: hcplive.com
Related Topics:
United StatesPbruce SandsPraveen TipirneniHenryd JanowitzAlimentiv Bruce SandsMount Sinai Health SystemUnited European Gastroenterology WeekMount Sinai HealthRobarts Histopathology IndexMayo Composite ScorePresent PositiveSevere Ulcerative ColitisMorphic Reports Positive Topline ResultsOrally AdministeredPrimary EndpointOpen Label StudyAdults WithInflammatory Bowel DiseaseUlcerative ColitisEmerald 1Emerald 2Morf 057Morphic TherapeuticTopline Results
Morphic Announces Corporate Highlights and Financial - Vimarsana News

Morphic Announces Corporate Highlights and Financial

Published: April 25, 2023

-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and demonstrates clinically meaningful improvements...

Source: globenewswire.com
Related Topics:
United StatesPraveen TipirneniChris ErdmanMorphic Holding IncExchange CommissionSecurities ExchangeColitis Organization Annual MeetingRecent CorporateRobarts Histopathology IndexModified Mayo Clinic ScoreEuropean CrohnChief Executive OfficerFirst QuarterSecurities ActSecurities Exchange ActPrivate Securities Litigation Reform ActAnnual ReportQuarterly ReportConsolidated StatementsMonths Ended MarchConsolidated Balance SheetsNasdaq MorfMorphic TherapeuticMorf 057Ulcerative Colitis